



Atty Dkt No. 01-0159-CIP2
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:
Ibrahim, et al.

Confirmation No.: Not Assigned

Serial No.: 10/759,562

Group Art Unit: Not Assigned

Filing Date: January 16, 2004

Examiner: Not Assigned

Title: Substituted Heterocyclic Compounds

INFORMATION DISCLOSURE STATEMENT

Mail Stop IDS
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. Applicants respectfully request that the Examiner review and make of record the references identified below.

The references identified below were disclosed and/or cited in parent application Serial No. 10/346,684, filed January 17, 2003. As such, copies of the references are not included pursuant to the provisions of 37 CFR § 1.98(d).

A PTO-1449 form listing the references accompanies this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record. The references are as follows:

U.S. PATENT DOCUMENTS		
Document No.	Issue Date or Publication Date	Name of Patentee or Applicant
4,567,264	Kluge et al	January 28, 1986
6,451,798	Varkhedkar et al	September 17, 2002
6,552,023	Zablocki et al	April 22, 2003
6,573,264	Zablocki et al	June 3, 2003


As the subject application was filed after June 30, 2003, copies of the U.S. patents and/or publications disclosed in this Information Disclosure Statement are not required and, therefore, are not included.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any of the above references constitutes prior art to the present application within the meaning of 35 USC § 102.

As applicants have not yet received a first Action on the merits, no fee is required for filing this Information Disclosure Statement. If, however, the PTO finds that for some reason a fee is found to be necessary, our Deposit Account No. 50-1789 may be charged therefor.

Respectfully submitted,

By:



J. Elin Hartrum
Registration No. 43,663


CV Therapeutics, Inc.
3172 Porter Drive
Palo Alto, California 94304
Telephone: (650) 384-8755
Facsimile: (650) 475-0359

S:\LEGALCVT\Patent\Docs\01-159\CIP 2\IDS.DOC

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/759,562
Filing Date	January 16, 2004
First Named Inventor	Prabha Ibrahim
Art Unit	1623
Examiner Name	
Attorney Docket Number	01-0159-CIP2

Sheet	1	of	1
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document No.	Issue Date or Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date if Appropriate
		4,567,264	Kluge et al	January 28, 1986			
		6,451,798	Varkhedkar et al	September 17, 2002			
		6,552,023	Zablocki et al	April 22, 2003			
		6,573,264	Zablocki et al	June 3, 2003			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document No.	Publication Date	Country	Class	Subclass	T

OTHER DOCUMENTS — NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), Title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.